Cargando…
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
BACKGROUND: Methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter is a favorable prognostic factor in glioblastoma patients. However, reported methylation frequencies vary significantly partly due to lack of consensus in the choice of analytical method. METHOD: We examined...
Autores principales: | Håvik, Annette Bentsen, Brandal, Petter, Honne, Hilde, Dahlback, Hanne-Sofie Spenning, Scheie, David, Hektoen, Merete, Meling, Torstein Ragnar, Helseth, Eirik, Heim, Sverre, Lothe, Ragnhild A, Lind, Guro Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311573/ https://www.ncbi.nlm.nih.gov/pubmed/22390413 http://dx.doi.org/10.1186/1479-5876-10-36 |
Ejemplares similares
-
Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment
por: Jeanmougin, Marine, et al.
Publicado: (2020) -
Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma
por: Andresen, Kim, et al.
Publicado: (2015) -
CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers
por: Vedeld, Hege Marie, et al.
Publicado: (2017) -
Genomic characterization of ependymomas reveals 6q loss as the most common aberration
por: OLSEN, THALE KRISTIN, et al.
Publicado: (2014) -
Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients
por: Estival, Anna, et al.
Publicado: (2019)